Investigation and analysis of 3-year survival and influencing factors in patients with primary gastric cancer

Table 1 Comparison of the clinical data between the two groups, n (%)

Index		Survival group (n = 73)	Death group (n = 27)	χ2/Z	P value
Sex	Male	38 (52.05)	15 (55.56)	0.097	0.755
	Female	35 (47.95)	12 (44.44)
Age (year)	< 60	60 (82.19)	14 (51.85)	9.430	0.002
	≥ 60	13 (17.81)	13 (48.15)
ASA	I-II	58 (79.45)	15 (55.56)	5.710	0.017
	≥ III	15 (20.55)	12 (44.44)
The located of tumor	Sinuses ventriculi	21 (28.77)	9 (33.33)	0.273	0.785
	Corpora ventriculi	30 (41.10)	10 (37.04)
	Preventriculus	22 (30.14)	8 (29.63)
Drink	Yes	26 (35.62)	14 (64.38)	2.165	0.141
	No	47 (51.85)	13 (48.15)
Smoke	Yes	23 (31.51)	10 (37.04)	0.273	0.602
	No	50 (68.49)	17 (62.96)
The degree of tumor differentiation	Tall	14 (19.18)	4 (14.81)	1.288	0.198
	Centre	26 (35.62)	6 (22.22)
	Below	33 (45.21)	17 (62.96)
TNM	Phase 1	36 (49.32)	5 (18.52)	3.847	< 0.001
	Phase 2	29 (39.73)	7 (25.93)
	Phase 3	8 (10.96)	15 (55.56)
Pathology type	Adenocarcinoma	39 (53.42)	15 (55.56)	0.343	0.731
	Mucinous adenocarcinoma	16 (21.92)	7 (25.93)
	Signet ring cell cancer	18 (24.66)	5 (18.52)
Tumor diameter	≤ 5 cm	44 (60.27)	10 (37.04)	4.284	0.038
	> 5 cm	29 (39.73)	17 (62.96)
Infiltration depth	T1 + T2	41 (56.16)	9 (33.33)	4.110	0.043
	T3 + T4	32 (43.84)	18 (66.67)
Lymphatic metastasis	Yes	20 (27.40)	15 (55.56)	6.870	0.009
	No	53 (72.60)	12 (44.44)
Nodal dissection	Yes	50 (68.49)	12 (44.44)	4.838	0.028
	No	23 (31.51)	15 (55.56)
Postoperative adjuvant chemoradiation therapy	Yes	52 (71.23)	11 (40.74)	7.862	0.005
	No	21 (28.77)	16 (59.26)
Postoperative CEA level	< 5 ng/mL	45 (61.64)	10 (37.04)	4.822	0.028
	≥ 5 mL	28 (38.36)	17 (62.96)
Operation time	≥ 3.5 hours	22 (30.14)	16 (59.26)	7.095	0.008
	< 3.5 hours	51 (69.86)	17 (40.74)
Intraoperative bleeding	≥ 200 mL	31 (42.47)	12 (44.44)	0.031	0.859
	< 200 mL	42 (57.53)	15 (55.56)
Gastrectomy range	Total gastrectomy	24 (32.88)	15 (55.56)	4.261	0.039
	The stomach was excised in large parts	49 (67.12)	12 (44.44)
Surgical effect	Complete remission	22 (30.14)	9 (33.33)	0.464	0.642
	Partial remission	29 (39.73)	8 (29.63)
	Stable disease	20 (27.40)	6 (22.22)
	Progression disease	2 (2.74)	4 (14.81)
Postoperative complications	Yes	22 (30.14)	14 (51.85)	4.034	0.045
	No	51 (69.86)	13 (48.15)

ASA: American Society of Anesthesiologists; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen.

Table 2 Variable assignment methods for multivariate logistic regression analysis

Variable	Value
Age	0: < 60, 1: ≥ 60
ASA	0: I-II, 1: ≥ III
TNM	0: I, 1: II, 2: III
Tumor diameter	0: I-II, 1: ≥ III
Infiltration depth	0: ≤ 5 cm, 1: >5 cm
Lymphatic metastasis	0: Yes, 1: No
Nodal dissection	0: Yes, 1: No
Postoperative adjuvant chemoradiation therapy	0: Yes, 1: No
Postoperative CEA level	0: < 5 ng/mL, 1: ≥ 5 ng/mL
Operation time	0: ≥ 3.5 hours, 1: < 3.5 hours
Gastrectomy range	0: Total gastrectomy, 1: The stomach was excised in large parts
Postoperative complications have occurred	0: Yes, 1: No

0: Absence; 1: Presence; ASA: American Society of Anesthesiologists; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen.

Table 3 Analysis of factors influencing survival at 3 years after laparoscopic surgery in patients with primary gastric cancer

Variable	β	SD	Wald χ2	P value	OR	95%CI
Age	1.141	0.216	6.878	0.004	0.579	0.501-0.874
ASA	0.710	0.436	5.437	0.112	2.114	1.704-5.413
TNM	0.844	0.325	6.258	0.003	2.103	1.687-5.144
Tumor diameter	0.541	0.623	3.145	0.022	1.479	1.198-2.369
Infiltration depth
Lymphatic metastasis	1.204	0.211	10.782	< 0.001	2.009	1.325-5.697
Nodal dissection	1.397	0.159	9.456	0.002	0.789	0.514-0.988
Postoperative adjuvant chemoradiation therapy	1.114	0.279	9.887	< 0.001	0.611	0.514-0.892
Postoperative CEA level	1.354	0.778	9.146	< 0.001	1.556	1.045-2.984
Operation time	0.571	0.246	6.445	0.012	1.687	1.014-2.778
Gastrectomy range	0.556	0.214	5.336	0.029	1.781	1.146-2.842
Postoperative complications have occurred	1.145	0.789	2.114	0.006	0.148	0.026-1.234

OR: Odds ratio; CI: Confidence interval; ASA: American Society of Anesthesiologists; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen.